Russian Research Center for Radiology and Surgical Technologies Federal Agency of High Medical Care Technology, Saint-Petersburg, 197758, Pesochny, Leningradskaya st., 70/4
Purpose: The evaluation of the hormonal changes in patients with metastatic prostate cancer after «hypophysectomy» by narrow proton beam as a stage of hormonal therapy.
Material and Methods: 98 patients with disseminated prostate cancer had been irradiating on the synchrocyclotron PNPI (1000 MeV, Gatchina). Because of the high energy of the proton beam the rotating-convergent shoot-through technique had been using. The single dose of 80-100 Gy had been giving. The levels of prolactin, testosterone, cortisol and PSA had been evaluated before and annually after proton therapy in two groups of the patients: with the stabilization (n=46) and the progression (n=25) of the disease.
Results: In the patients with the progression of the disease during the first year of study the level of prolactin was significantly higher (374,7±13,8 mME/l) than in the patients with the stabilization (203,9±8,0 mME/l, <0,05). A direct correlation between the levels of prolactin and PSA was detected (r=0,937 p<0,0001). The changes of testosterone level were not significant. The level of cortisol in the patients with the stabilization was significantly higher (566,4±18 nmol/l, p<0,05), than in the patients with the progression of the disease (352,5±14,94 nmol/l). An inverse correlation between the levels of cortisol and PSA was detected (r=-0,975 p<0,0001).
Conclusion: Proton «hypophysectomy» is the stage of systemic therapy of patients with metastatic prostate cancer. Monitoring of hormonal changes is of great importance for palliative care of such patients.
1. Belchenko L.V., Kirpatovskaya L.E., Marova E.I. i dr. Fynkcionalnoe sostoyanie adenogipofiza pri bolezni Icenko-Kyshinga do i posle oblycheniya ego protonnim pychkom.-Jyrn. Vopr. neirohiryrgii im. N.N. Byrdenko, 1989, vip. 5, S.31-32
8. Boyle P.,Maisonneuve P.,Napalkov P.Incidence of prostate cancer will double by the year 2030:arguments//Europ.J.Urol.– 1996.–Vol.29 (suppl.2).–P.3 –9..
9. DeVita V. Cancer of the prostate//In: Cancer, Principles and Practice of Oncology, 2nd Edition.- Lippincott J.- Pennsylvania.- 1985.-P.929-957. 7Newling D. W., Dennis I., Vermeylen K. // Cancer. — 1993. — Vol. 72. - Suppl. - P. 3793- 3798